IRD
Opus Genetics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.67
+1.52%Margins
Gross margin
99.9%
EBITDA margin
-1064.6%
EBIT margin
-513.5%
Net margin
-1091.8%
FCF margin
-412.6%
828.7%
Return on equity
-115.7%
Return on assets
-230.6%
Return on invested capital
0.12x
Asset turnover
-$40.7M
Cash from operations
$1.07
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026